The Procter Gamble Company

Biovinc LLC

University of Southern California

Norwich Eaton Pharmaceuticals, Inc.

Isis Innovation Limited

Warner Chilcott Company, LLC

University of California

University of Rochester

Other

Wisconsin Alumni Research Foundation

The United States Government as Represented by the Department of Veterans Affairs

Indiana University

Procter & Gamble Pharmaceuticals, Inc.

Procter & Gample Pharmaceuticals, Inc.

P&g Pharmaceuticals, Inc.

Frank Hallock Ebetino

Adam W Mazur

Marion David Francis

Mark Walden Lundy

Susan Mary Kaas

Charles E McKenna

Shuting Sun

Keivan Sadrerafi

James J Benedict

Wieslaw Adam Mazur

Jocelyn E McOsker

Kent W Buckingham

Xinrong Tian

Roy Lee Martin Dobson

John M Janusz

John August Wos

Russell James Sheldon

Xiufeng Eric Hu

Ichiro Nishimura

Dennis G Nelson

Akishige Hokugo

Brendan F Boyce

Feng Wang

Eric T Richard

Robert Graham Russell

Parish Sedghizadeh

Philip T Cherian

Lifeng Xiao

Susan Mary Dansereau

Allan Vincent Bayless

Robert K Boeckman

Biswanath De

Andrew S Kende

Mitchell Anthony DeLong

Mark Gregory Solinsky

Christopher A Bradfield

Lianping Xing

Jesus Delgado-Calle

G David Roodman

Teresita M Bellido

Alan P Poland

Robert Kenneth Boeckman, Jr

Edward N Glover

Xinyi Song

Zhenqiang Yao

Philip Cherian

Robert Boeckman

Anny-Odile Colson

Xuewei Liu

Adam Wieslaw Mazur

Robert Kenneth Boeckman

Brendan Boyce

Robert Graham Goodwin Russell

Described herein are bisphosphonate oxazolidinone compounds, and conjugates and pharmaceutical formulations thereof, that can include a bisphosphonate and an oxazolidinone (or an oxazolidinone antimicrobial or antibiotic agent, substituent or derivative thereof), where the oxazolidinone can be releasably coupled to the bisphosphonate. Also provided herein are methods of making and methods of using the bisphosphonate oxazolidinone compounds, conjugates and pharmaceutical formulations thereof. Also provided herein are methods of use of the compounds, conjugates and formulations for treating a bone disease or for use in preparing a formulation for the treatment a bone disease.

Bone targeted antimicrobial oxazolidinone related compounds, formulations thereof, and uses thereof

Described herein are bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof that can include a bisphosphonate and a quinolone, where the quinolone can be releasably coupled to the bisphosphonate. Also provided herein are methods of making and methods of using the bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof.

Bisphosphonate quinolone conjugates and uses thereof

Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistance to the treatment, prevention, and diagnosis of diseases/symptoms induced by multiple myeloma. Embodiments include methods of treating a bone related disease, comprising the steps of: administering to a subject at least one therapeutically effective dose of a compound disclosed herein.

Materials and methods for suppressing and/or treating bone related diseases and symptoms

The present invention provides compositions and methods for providing controllable local delivery of a conjugate of bortezomib (Btz) and a bisphosphonate to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with diseases and disorders characterized by bone loss.

Bortezomib conjugates and methods using same

Disclosed herein are methods and compositions for removing or displacing bisphosphonates in skeletal tissue.

Skeletal removal of bisphosphonates

The present invention provides compositions and methods for providing controllable local delivery of a conjugate of chloroquine (CQ) and a bisphosphonate to treat diseases characterized by abnormal bone metabolism. In certain embodiments, the invention is used as a treatment for a subject with diseases and disorders characterized by bone loss.

Phosphonate-chloroquine conjugates and methods using same

Novel bisphosphonate cyclic acetal compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating bone metabolism disorders, such as abnormal calcium and phosphate metabolism.

Bisphosphonate compounds

Novel imidazo[1,2-&#x3b1;]pyridinyl bisphosphonate compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating abnormal calcium and phosphate metabolism, including bone and joint diseases and other disorders.

Imidazo[1,2-a] pyridinyl bisphosphonates

Novel 5-azaindole bisphosphonate compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating abnormal calcium and phosphate metabolism, including bone and joint diseases and other disorders.

5-azaindole bisphosphonates

Disclosed is a new composition of matter, substantially enantiomerically pure (1R,6S)-2-Azabicyclo-[4.3.0]nonane-8,8-diphosphonic acid, methods of preparing this new composition of matter, a pharmaceutical composition comprising the new composition, and administration of the composition in methods of treating bone disorders such as osteoporosis, osteolytic bone metastasis, rheumatoid arthritis and osteoarthritis.

Composition for treating bone disorders

The present invention relates to compounds which comprise a nitrogen-containing ring scaffold substituted by an Ralkyl units selected from the group consisting of C&#x2013;Clinear or branched alkyl, C&#x2013;Ccyclic alkyl, C&#x2013;Clinear or branched alkenyl, or haloalkyl, for example, the 2-keto-3-alkylpiperazines having the formula: wherein R is selected from the group consisting of phenyl, 3-fluorophenyl, 4-fluorophenyl, 3,5-difluorophenyl, and 4-chlorophenyl; Ris selected from the group consisting of methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, benzyl, allyl, 1-methylallyl, 2-methylallyl, but-2-enyl, and propargyll; Ris selected from the group consisting of hydrogen, &#x2014;COH, &#x2014;CONH, &#x2014;CONHCH, and &#x2014;CON(CH); Ris benzyl, substituted benzyl, or naphthalen-2-ylmethyl.

Melanocortin receptor ligands

Growing community of inventors

Cincinnati, OH, United States of America

Frank Hallock Ebetino